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Exopolysaccharide (EPS)-producing bifidobacteria, particularly Bifidobacterium animalis
subsp. lactis strains, are used in the functional food industry as promising probiotics
with purported beneficial effects. We used three isogenic strains of B. animalis subsp.
lactis, with different EPS producing phenotypes (mucoid-ropy and non-ropy), in order
to determine their capability to survive the murine gastrointestinal tract transit, as well
as to evaluate their role in improving clinical outcomes in a chemically-induced colitis
model. The three strains were able to survive in the intestinal tract of C57BL/6J mice
during the course of the intervention study. Furthermore, the disease activity index (DAI)
of the animal group treated with the ropy strain was significantly lower than of the DAI
of the placebo group at the end of the treatment. However, no significant differences
were found among the three strains. The analysis of several immune parameters, such
as TNFα and IL-10 quantified in blood plasma and lymphocyte populations enumerated
in mesenteric nodes, showed some significant variations among the four experimental
animal groups. Remarkably, a higher capability of the ropy strain to increase regulatory
T-cells in mesenteric lymphoid nodes was demonstrated, suggesting a higher ability of
this strain to regulate inflammatory responses at mucosal level. Our data indicate that
strains of B. animalis subsp. lactis producing EPS that confer a mucoid-ropy phenotype
could represent promising candidates to perform further studies targeting intestinal
inflammatory processes.
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INTRODUCTION
The human gut is one of the most densely populated ecosystems
inhabited by a community of microorganisms that actively
contributes to the health of the host. Microbiota establishes a
symbiotic relationship with the host, but also their members
must co-exist in a balanced state. Indeed, disturbances in
microbiota composition (dysbiosis) and function, as well as
in the microbiota-host cross-talk, are the basis of prevalent
gastrointestinal diseases, and also of some extra-intestinal
pathology (Tojo et al., 2014). Among others, microbiota shifts
have been related to chronic inflammatory disorders, such as
inflammatory bowel disease (IBD) (Huttenhower et al., 2014). Up
to now, dietary interventions toward restoring the unbalanced
microbiota, such as the oral administration of probiotics, have
been a realistic approach for human applications (Reid et al.,
2011; Collins, 2014). Hill et al. (2014) have recently reviewed
the probiotic concept and they have adopted, with a minor
grammatical correction, the definition “live microorganisms
that, when administered in adequate amounts, confer a health
benefit on the host,” previously proposed by the FAO and WHO
organizations (FAO/WHO. Food and Agricultural Organization
of the United Nations and World Health Organization, 2001).
Research on probiotics has generated a vast amount of literature,
mainly related to the characterisation of the probiotic potential
of Lactobacillus and Bifidobacterium, the genera most commonly
used for human consumption. However, only a small number of
strains have been evaluated for the prevention or treatment of
gastrointestinal disorders, such as IBD, diverse diarrheas, irritable
bowel syndrome (IBS) or necrotising enterocolitis (NEC) (WGO.
World Gastroenterology Organisation, 2011; Sanders et al.,
2013). In relation to bifidobacteria, specific strains belonging
to the species Bifidobacterium breve, Bifidobacterium longum,
Bifidobacterium bifidum, and Bifidobacterium animalis subsp.
lactis, have been tested in human intervention studies resulting
in positive effects on gastrointestinal dysfunctions (Tojo et al.,
2014).
B. animalis subsp. lactis is the species that has been most
successfully introduced in food formulations, since it is able
to deal with technological challenges during food manufacture
(Prasanna et al., 2014). However, analysis of the available
genomes shows a very low genetic variability among members of
this subspecies (Milani et al., 2013). One of the features shared in
all of their genomes is the presence of a cluster involved in the
synthesis of exopolysaccharides (EPS) which are carbohydrate
polymers surrounding the cell wall (Hidalgo-Cantabrana et al.,
2014b). These EPS play a relevant role for the producing strain
because they are involved in protection and niche colonization,
but EPS also act as intermediaries in the dialog established
between bacteria and host (Hidalgo-Cantabrana et al., 2014b). It
has been proposed that EPS are able to interact with receptors
located in the gut epithelium (Lebeer et al., 2010b) and they could
act as effector molecules eliciting different immune responses
(Hidalgo-Cantabrana et al., 2012).
In recent years our group has been working on the study
of biological properties of EPS synthesized by bifidobacteria.
One of the B. animalis subsp. lactis strains from our collection
displayed a mucoid-ropy phenotype, denoted by the formation
of a long filament from the colony, and it was able to synthesize
a high molecular weight (HMW)-EPS. Recently, working with
three recombinant strains, we demonstrated the involvement of
a mutation (C> 266 >T) in wzz gene in the occurrence of this
phenotype and in the synthesis of the HMW-EPS fraction. This
gene encodes a hypothetical membrane anchored protein, with a
predicted large soluble domain, which is theoretically involved
in the chain length determination of the polymer (Hidalgo-
Cantabrana et al., 2015). The acquisition of the ropy phenotype
favored the in vitro survival and adhesion of the recombinant
strain to the gut environment. In turn, this strain also elicited an
in vitro and ex vivo anti-inflammatory cytokine profile (Hidalgo-
Cantabrana et al., 2015). Thus, in a step forward the current
work aims to in vivo evaluate the probiotic potential of the ropy
B. animalis subsp. lactis Balat_1410S89L checking its capability
to counteract an inflamed state of colitis chemically induced by
dextran sodium sulfate (DSS) administration.
MATERIALS AND METHODS
Bifidobacterial Strains and Preparation of
Lyophilized Bacteria in Milk
Three isogenic EPS-producing B. animalis subsp. lactis strains
from the IPLA-CSIC collection were used in this study to
test their probiotic capabilities in an in vivo model. Based on
the type strain DSM10140, recombinant strains were obtained
from a previous study (Hidalgo-Cantabrana et al., 2015):
strain 1Balat_1410 (DSM10140 lacking the gene Balat_1410
complemented with pAM1, non ropy), strain Balat_1410 (strain
1Balat_1410 complemented with pAM1 + Balat_1410, non
ropy), and Balat_1410S89L (strain 1Balat_1410 complemented
with pAM1 + Balat_1410S89L, ropy). Glycerol stocks kept at
−80◦C were plated on agar MRSC [MRS Difco (BD, Biosciences,
San Diego, CA) containing 0.25% L-cysteine-HCl (Sigma-
Chemical Co., St. Louis, MO)] supplemented with erythromycin
(2.5 µg/ml) (MRSCE). Plates were incubated at 37◦C under
anaerobic conditions (80% N2, 10% CO2, 10% H2) in an MG500
chamber (Don Whitley Scientific, West Yorkshire, UK). A single
colony per strain was used to inoculate 50 ml MRSCE broth
and after 20 h this culture was used to inoculate 2% (v/v) 1 L
fresh medium. After 20 h incubation, cultures were centrifuged,
washed once with PBS and resuspended in 100 ml tindalized 11%
skimmed milk (Difco). Then, bacterial suspensions in milk were
lyophilized for 48 h in the Virtis Freezemobile 12EL equipment
(SP Scientific, NY). Each lyophilized bifidobacterial stock was
tested for bacterial viability and enumeration by counting in
agar-MRSCE and incubated under standard conditions. For oral
administration, each lyophilized bifidobacteria was resuspended
daily in water (at 5 × 109 cfu/ml) and 100 µl was administered
per mouse.
Animals, Experimental Designs and
Sample Collection
All studies were carried out following the Directive 2010/63/EU
of the European Parliament and the Council on the protection
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of animals used for scientific purposes (Directive 2010/63/EU,
2010). The experimental protocol was approved by the Ethical
Committee of Laboratory Animals of the University of Granada
(Spain) (Permit Number CEEA-2010-286). Male C57BL/6J mice
(7–9 weeks old, approximately 20 g) were obtained from Janvier
Labs (St Berthevin Cedex, France) and kept under conventional
conditions with a standard pelleted diet and sterilized water for 1
week before beginning the experiments.
Bifidobacteria Survival Study
Animals (32 mice) were randomly assigned to four experimental
groups with 8 mice per group: three bifidobacterial groups, each
orally receiving 100 µl/day (5 × 108 cfu) of the corresponding
milk-bifidobacterial suspension in water, and one placebo
(control) group which received 100 µl/day of skimmed milk.
Placebo and bifidobacteria suspensions were orally administered
for 9 days by means of an intra-gastric cannula. Every day, the
drinking water and food intake was measured for each group of
mice, whereas the body weight was measured individually for
each animal. Stool samples were taken, in duplicate, at group
level every 2 days, including the first and last day. At the end of
the intervention period (day 10), each mouse was anesthetized
with isoflurane and then, the animals were sacrificed by cervical
dislocation by expert and qualified persons, according to the
Federation of European Laboratory Animal Science Associations
(FELASA). The colon was excised, its content was collected and
its length and weight was measured after washing with PBS.
Stool and colon-content samples were immediately processed as
described in the next section.
Dextran Sodium Sulfate (DSS) Induced Colitis Study
Mice (40 animals) were randomly assigned to five groups,
each with 8 animals, as described in Figure 1. The reference
(non-colitic, non-placebo/bifidobacteria fed) group received
daily, through an intra-gastric cannula, 100 µl water during
the 15-day experimental period. The other four groups
were fed with bifidobacteria, or a placebo, and treated with
DSS. During the 15 days of the experimental period these
four groups received a placebo (100 µl/day milk, group
1), or different bifidobacterial strains (100 µl/day 5 × 108
cfu milk-bifidobacterial suspensions in water, for groups 2,
3, and 4). After 9 days of bifidobacteria/placebo feeding,
colitis was induced in the four groups by adding DSS
(3%, w/v, 36–50 kDa, MP Biomedicals, CA) in the drinking
water (Mähler et al., 1998). This DSS-treatment was kept
for a period of 6 days unless the application of humane
end-point, as defined below, was needed. At the end of
the experimental period (day 15) animals were anesthetized
and a blood sample was directly extracted from the heart
using heparinized tubes. The blood plasma was obtained by
centrifugation (9,300xg, 4◦C, 20 min). The animals were then
euthanatized in order to collect colon and colon-content, as
described above, as well as mesenteric lymphoid nodes. Samples
were immediately processed or stored at −20◦C until their
analysis.
Drinking water and food intake was measured at group
level each day, whereas body weight, stool consistency and the
presence of gross blood in feces were evaluated daily and scored
(Table 1) for each mouse during the experimental period. The
disease activity index (DAI) was calculated as previously reported
by Cooper et al. (1993): total score [body weight decrease+ stool
consistency + rectal bleeding] / 3. The ulcerative colitis (UC)
disease is considered for DAI ≥ 1.5 and the humane endpoint
was fixed at DAI = 3. Stool samples were taken at group level
every 2 days to check viability of bifidobacteria.
Microbial Quantification in Fecal Samples
Bifidobacterial Quantification by Counting
Stool samples, collected in both studies as previously indicated,
were homogenized in PBS (0.1 g/ml) using a Heidolph (Heidolph
Instruments GmbH, Schwabach, Germany) stirrer for 1 min.
Then, 100 µl was used to obtain serial dilutions in PBS
which were plated onto the surface of TOS propionate agar
medium (Merck, Darmstadt, Germany), supplemented with
lithium-mupirocin as recommended by the manufacturer, to
selectively enumerate total bifidobacteria. Additionally, agar
lithium-mupirocin-TOS was supplemented with 2.5 µg/ml
erythromycin (TOS+Ery) which is the selective marker of the
plasmid present in the three B. animalis subsp. lactis strains
under study. All plates were incubated at 37◦C in an anaerobic
jar using Oxoid-AnaerogenTM (Thermo Fisher Scientific Inc.,
Waltham, MA) sachets to generate anaerobic conditions
for 72 h.
Bifidobacterial Identification by 16S rDNA
Amplification
Several colonies were picked up from TOS+Ery plates of each
of the four experimental groups belonging to the bifidobacteria
survival study. The DNA from a total of 67 colonies was
isolated using the GenElute Bacterial Genomic DNA kit (Sigma)
according to the manufacturer’s instructions, but adding a
prior step of bacterial lysis with mutanolysin and lysozyme.
Primer uses were: pA/pH (Edwards et al., 1989). The PCR
mixture (final volume 50 µl) was: 1 µl chromosomal DNA, 0.20
µM of each primer, 200 µM dNTPs (Amersham Bioscience,
Upsala, Sweden) and 2.5 U Taq DNA-polymerase (Eppendorf,
Hamburg, Germany). After an initial cycle at 95◦C, the PCR
amplification consisted of 30 cycles: 95◦C for 1 min, 55◦C for
50 s and 68◦C for 2 min, and ended with a final extension
step of 68◦C for 10 min. Reactions were carried out in the
thermal cycler UnoCycler (VWR International Eurolab S.L.,
Barcelona, Spain). Purification and sequencing of the amplicons
were performed in Macrogen (Seoul, Korea). The free Chromas
1.45 software (Technelysium Pty Ltd., Australia) was used
to process sequences which were compared to those held in
the GenBank database (http://www.ncbi.nlm.nih.gov/genbank)
using the BLASTn tool.
Gene Expression Analyses in Colonic
Samples by Reverse Transcriptase qPCR
After colon excision, PBS-washed colonic tissue was sectioned
in small fragments which were placed in RNAlater stabilization
reagent (Qiagen GmbH, Hilden, Germany) and then stored
at −80◦C until RNA extraction. Total RNA was isolated using
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FIGURE 1 | Experimental design to check the capability of EPS-producing B. animalis subsp. lactis strains to counteract the dextran sodium sulfate
(DSS)-induced colitis. Group 1 (placebo) daily receiving 100 µl skimmed milk and Groups 2–4 daily receiving 100 µl milk with 5 × 108 cfu bifidobacteria: group 2,
strain 1Balat_1410 (DSM10140 lacking the gene Balat_1410 complemented with pAM1, non ropy); group 3, strain Balat_1410 (strain 1Balat_1410 complemented
with pAM1 + Balat_1410, producing a non-ropy EPS); group 4, strain Balat_1410S89L (strain 1Balat_1410 complemented with pAM1 + Balat_1410S89L, producing
a ropy EPS). Reference group (non DSS-induced colitis, non-placebo/bifidobacteria fed group) daily receiving 100 µl water.
TABLE 1 | Disease activity index (DAI) score used to evaluate the
DSS-induced colitis. DAI index was calculated as total score (body weight
decrease + stool consistency + rectal bleeding) divided by 3.
Score Body weight decrease (%) Stool consistency Rectal bleeding
0 <1 Normal Normal
1 1–5
2 5–10 Loose stools
3 10–20
4 >20 Diarrhea Gross bleeding
The humane end-point was established at DAI = 3.
RNeasy Mini Kit (Qiagen) according to the manufacturer’s
recommendations. Purity and RNA concentration were
determined with the NanoDropTM 2000 spectrophotometer.
Then, 3 µg RNA was reverse transcribed to obtain cDNA
using oligo(dT) primers and reagents from Promega (Promega,
Southampton, UK) and the TProfessional basic thermocycler
(Biometra GmbH, Goettingen Germany).
The amplification was performed in an EcoTM Real-Time PCR
System (Illumina, San Diego, CA USA) using 20 ng of cDNA
and specific primers (Table S1). The 2−11Ct method was used
to normalize expression results (Livak and Schmittgen, 2001).
The values of the house-keeping glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) gene were first used to normalize the
values obtained for each of the genes under study. These values
were additionally normalized to those obtained in the reference
group, thus this group had a normalized value of 0. Finally the
relative expression of each gene was calculated as 2−11Ct, thus
the reference group had the relative expression value of 1.
Cellular Population in Mesenteric
Lymphoid Nodes
The mesenteric lymphoid nodes were carefully mashed with
wet slides to decrease friction and the solutions were filtered
through a 70 µM cell strainer. Cells were isolated, counted
and plated on anti-CD3 (clone17A2, eBioscience, San Diego,
CA, USA) and anti-CD28 (clone 37.51, eBioscience)—coated
plates for FcγR blocking. Then, the cells were transferred to
polystyrene tubes for surface staining with anti-CD4 (PerCP-
CyTM5.5, clone RM4-5 BD PharmigenTM, Franklin Lake, NU,
USA), anti-CD45 (APC-eFluor R©780, clone 30-F11, eBioscience)
and Viability Dye (eFluor R©660, eBioscience) for 15 min at
4◦C in the dark. The cells were then fixed, permeabilized with
the Fixation/Permeabilization kit (eBioscience) and intracellular
staining was done with anti-Foxp3 (PE, clone FJK-16s,
eBioscience) for 30 min at 4◦C in the dark. Data collection was
performed using a flow cytometer CANTO II (BD Biosciences
San Diego, CA, USA).
Cytokine Levels of Blood Samples
The levels of tumor necrosis factor (TNF)-α and interleukin
(IL)-10 cytokines in blood plasma were quantified using the
mouse TNFα Quantikine and mouse IL-10 Quantikine ELISA
kits (R&D Systems, Abingdon, UK) following the manufacturer’s
instructions.
Statistical Analyses
All considered variables were distributed normally (Kolmogorov-
Smirnov test was used to check normality); thus, they are
described as mean ± standard deviation. Robust Student-Welch
or ANOVA tests were used in order to check the equality among
groups for all variables, and post-hoc T3 de Dunnet or LSD
tests were used to compare each two groups. Standard linear
regressionmodels were employed to compute the size of the effect
(95% confidence interval) of the different treatments on the DAI;
to do this, crude data were adjusted by the initial conditions (DAI
score the first day of DSS-induced colitis) and the placebo group
was used as reference. Differences below 0.05 were considered
statistically significant. All analyses were made with the free
statistical software R (www.r-project.org).
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RESULTS AND DISCUSSION
B. animalis subsp. lactis Strains Are Able
to Colonize the Murine Gut
Orally administered probiotics should survive the upper
gastrointestinal tract (GIT) transit and reach the colon alive,
where they should persist for a certain time in order to be able to
exert their beneficial effect. Therefore, an animal experimentation
procedure was done to assess the viability of the three B. animalis
subsp. lactis strains under study aiming to check whether the
presence of the ropy HMW-EPS surrounding Balat_1410S89L
strain could exert a protective role. Additionally, although
B. animalis has QPS (qualified presumption of safety) status
(EFSA BIOHAZ Panel, 2013), we evaluated the lack of toxicity
of our strains, at this oral-dose administered to the animals, by
measuring animal behavior and wellbeing parameters. In this
regard, no differences (p > 0.05) were found in water and food
intake, body weight, stool consistency or colon anatomy between
the placebo (skimmed milk-fed) and each of the bifidobacteria-
fed groups (Table 2). These results support the fact that the three
bifidobacterial strains used in this study had no side effects at the
concentration level administered to this murine model.
The bifidobacterial population in the fecal samples was
enumerated using agar-TOS (Figure 2A) which is a selective
medium for bifidobacteria growing in milk products. After 2
days of administration, the bifidobacterial levels increased in
all groups about 1 log unit, including the placebo receiving
skimmed milk. However, during prolonged treatment the
population of bifidobacteria in the placebo group tended to
decline to reach the initial values, whereas counts in the three
bifidobacteria-fed groups remained stable. Similarly, counts
obtained in TOS+Ery, which is the medium containing the
selective marker erythromycin of the plasmid present in the
three strains under study, were significantly higher (p < 0.05) in
the three bifidobacterial-fed groups with respect to the placebo
(Figure 2B). Levels of erythromycin-resistant bacteria in the
microbiota of placebo-fed mice were around 4 log units and
remained unaltered for the duration of the experimentation time.
After 2 days of administration, levels of erythromycin-resistant
bifidobacteria increased (on average) 0.7 log cfu/g in the mice
receiving bifidobacteria; the highest count increase (1.7 log cfu/g)
was reached after 4 days, remaining at similar values until the
end of the experimentation period. In general, no statistical
differences among the three bifidobacteria-fed groups were found
and, additionally, the colonies chosen to partially sequence the
gene 16S rDNA were identified as members of Bifidobacterium
genus; those isolated from Balat_1410S89L fed animals displayed
a ropy phenotype as well (see Table S2). Altogether, these results
show that our bifidobacterial strains were able to survive as
members of the intestinal microbiota of mice for at least 9 days,
following a daily intake of 5 × 108 cfu. The increase in total
bifidobacteria observed in this study could be related to the ability
of EPS-producing B. animalis subsp. lactis to raise the number
of other bifidobacterial species in the intestinal microbiota of
rodents as previously described (Salazar et al., 2011). This effect
could be related to the ability of members from this microbial
community to use EPS as fermentable substrates (Salazar et al.,
2009). However, the increase of erythromycin resistant members
in feces is indicative of a higher survival rate in the gut of the
specific strains used in this work. The in vivo performance of
the three strains is rather similar, since there was no statistical
difference in the number of bifidobacteria present in the fecal
samples among the three groups of mice. Thus, it seems that the
presence of HMW-EPS on the surface of the ropy Balat_1410S89L
strain does not confer an additional protection of survival in
mice gut. Fanning et al. (2012) found that fecal counts (made in
Reinforced Clostridium agar with 50 mg/L mupirocin) of mice
fed with EPS+ B. breve UCC2003 were significantly higher than
those obtained with two non-EPS producing mutant strains.
Thus, these authors conclude that the presence of an EPS on
the surface of the wild type B. breve was involved in its higher
survival rate in the mice gut. On the contrary, in vivo studies
carried out with different EPS-producing Lactobacillus johnsonii
strains showed that mutants with deletion of genes from the
eps cluster had an increased residence time in the animal’s gut
(Denou et al., 2008; Horn et al., 2013). It has also been shown
that the loss of EPS production in Lactobacillus rhamnosus GG
improves the in vitro adhesion of the strain to Caco2 cells (Lebeer
et al., 2009); however, the presence of the EPS surrounding the
wild type GG strain improves its in vivo performance allowing
the strain to persist for longer periods because the EPS protects
against the antimicrobial peptide LL-37 (Lebeer et al., 2010a).
The intrinsic characteristics of EPS, such as composition and size,
seem to promote different effects on bacterial survival under gut
challenges. In some cases, polymers could prevent the exposure
of molecules from the bacterial envelope involved in adhesion,
but EPS can also act as a shield against host immune defense
(Hidalgo-Cantabrana et al., 2012).
The Ropy B. animalis subsp. lactis
Balat_1410S89L Reduces DSS-Induced
Damage
As mentioned above, in vitro and ex vivo tests (using human
tissues) showed different immune modulation capabilities of
the three isogenic bifidobacteria, the ropy strain Balat_1410S89L
having an anti-inflammatory profile (Hidalgo-Cantabrana et al.,
2015). To expand on these observations, we wanted to address
whether this predicted anti-inflammatory ability is effective
in vivo, modifying the immune response in a model of gut
inflammation such as mice with DSS-induced colitis. This is a
well-established animal model of acute mucosal inflammation
that has been used for several decades (Wirtz et al., 2007) and
it has been validated as a model for the translation of mice data
to humans (Melgar et al., 2008).
In our experimental procedure, four groups of mice were pre-
treated with an oral administration of bifidobacteria, or placebo,
for 9 days before the administration of DSS in drinking water,
which was continued for an additional 6 days (Figure 1). As
was expected, in accordance with results shown in the previous
section, the pre-feeding for 9 days in the four groups did not
modify the wellbeing and behavior parameters of the mice. This
is also consistent with the absence of significant variations in
the disease activity index (DAI) score of these groups (values
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TABLE 2 | Mean and standard deviation of general parameters measured in four experimental groups of mice to evaluate the absence of toxicity of the
bifidobacterial strains administered for 10 days at dose of 5 × 108 cfu per mouse and day.
Experimentation group Food intakea Drink watera Body weigh increaseb Ratio weight/length of colonc
(g/mouse) (ml/mouse) (g) (%)
Placebo (skim milk) 2.22 ± 0.39 2.52 ± 0.48 0.73 ± 0.17 3.24 ± 0.75 0.024 ± 0.005
Strain 1Balat_1410 2.49 ± 0.23 2.79 ± 0.34 0.73 ± 0.16 3.20 ± 0.70 0.024 ± 0.009
Strain Balat_1410 2.24 ± 0.29 2.68 ± 0.45 0.85 ± 0.25 3.84 ± 1.13 0.025 ± 0.008
Strain Balat_1410S89L 2.18 ± 0.31 2.84 ± 0.51 0.66 ± 0.18 2.89 ± 0.78 0.026 ± 0.006
No significant statistical differences (p > 0.05) were found among the four experimental groups after one-way ANOVA study.
aValues obtained for the whole mice group for each day of experimental procedure.
bbody weight at day 10 subtracting the body weight measured at day 0 (27.71 ± 1.11) before the experimental procedure.
ccolon weight and length determined after 10 days of experimental procedure.
FIGURE 2 | Counts in agar-TOS to enumerate total bifidobacterial population (A) and agar-TOS+Ery (supplemented with 2.5 µg/ml erythromycin, the
antibiotic marker of strains under study) to enumerate erythromycin-resistant bacteria (B) in fecal homogenates obtained from four experimental
groups of mice along the experimental period. Placebo group ( ), feed B. animalis subsp. lactis 1Balat_1410 ( ), feed B. animalis subsp. lactis Balat_1410 ( ),
and feed B. animalis subsp. lactis Balat_1410S89L ( ). Within each treatment day: statistical differences with respect to the control group are marked with an asterisk
(p < 0.05) and differences among the three bifidobacterial groups are denoted with different letters (p < 0.05).
lower than 0.5, data not shown). The DAI score was kept close to
0 in the non-colitic, non-placebo/ bifidobacteria-fed (reference)
group during all experimental procedures. In the four colitic
groups, after the second day (day 11) of DSS treatment, the
DAI values increased continuously (Figure 3A). The maximum
score was obtained at the end of the experimental procedure,
after 6 days of DSS colitic induction. In general, no statistical
differences were detected on each day of treatment among the
placebo and the three bifidobacteria-fed groups during DSS-
treatment; the exception was the group fed with the strain
Balat_1410S89L, which showed a significantly (p < 0.05) lower
DAI score than the placebo group at day 15. These results
were confirmed when DAI data were adjusted by means of
linear regression models taking into consideration the DAI of
placebo group each day of DSS-induction (Figure 3B). This
model allowed us to determine the effect of the treatments
on the DAI with respect to the placebo (value = 0). Thus,
negative values of the adjusted DAI indicate a reduction in the
severity of the disease in comparison with the placebo group. The
highest reduction in adjusted DAI obtained for B. animalis subsp.
lactis Balat_1410S89L fed animals at the end of the treatment
was mainly associated with a reduction in diarrhea and rectal
bleeding. This led to a 44% reduction in the severity of the
disease with respect to the placebo (p < 0.007), whereas, in
the other two bifidobacteria-fed animals this reduction was not
statistically significant, although the reduction of the illness was
23.2% for the strain 1Balat_1410 and 16.7 % for the strain
Balat_1410. In spite of the remarkable differences among the
three strain-fed groups (disease severity in Balat_1410S89L was
reduced by almost two and three-fold compared to1Balat_1410
and Balat_1410, respectively), these differences were not deemed
statistically significant. Therefore, we cannot ascertain that the
protective effect against DSS-induced colitis exerted by strain B.
animalis subsp. lactis Balat_1410S89L is attributed to the HMW-
EPS surrounding the bacteria. Some authors have reported
the capability of probiotic strains to reduce the DAI index of
animals under DSS-induced colitis. However, a mixture of several
bacteria, or combinations of bacteria-bioactive compounds, are
often tested, thus the positive effect cannot be assigned to a single
bacterium (Dai et al., 2013). Only a few reports have shown the
efficacy of single bifidobacterial strains (Hayes et al., 2014; Zheng
et al., 2016).
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FIGURE 3 | Mean values of the disease activity index (DAI, Table 1) calculated for each experimental group. The coefficient of variation (SD/mean)
percentage of these values varied between 9 and 70%. Each bifidobacteria-fed group was compared with the placebo throughout the DSS-treatment and statistical
differences (p < 0.05) are marked with an asterisk (A). The DAI score of each bifidobacterial group was adjusted, as indicated in material and methods, to values of
placebo at the first day of DSS-treatment (value = 0). Negative values indicate a higher reduction in the disease severity with respect to the placebo. These adjusted
data were compared with placebo during the 5 days of DSS-treatment and statistical differences (p < 0.05) are marked with an asterisk (B). Reference group ( );
DSS-induced colitis groups: placebo ( ), feed B. animalis subsp. lactis 1Balat_1410 ( ), feed B. animalis subsp. lactis Balat_1410 ( ), feed B. animalis
subsp. lactis Balat_1410S89L ( ).
Different B. animalis subsp. lactis Strains
Elicit Specific Host Responses
In order to understand the mechanism(s) involved in the
attenuation of the DSS-colitis by the strain Balat_1410S89L
several immune parameters, targeting adaptive as well as innate
responses, were measured in different tissues. In our study,
the expression of several genes related to the reinforcement
of the intestinal epithelium barrier, such as those coding for
chemokines, proteins of tight junctions and mucins, showed no
statistical variations (p> 0.05) among the four groups of animals
(Table 3). Only the non-ropy EPS-producing strain Balat_1410
was able to slightly induce (p < 0.05) the expression of Mcp1,
a chemokine able to attract monocytes, as well as the secretory
protein TFF3, which is synthetized by goblet cells and acts to
stabilize the mucus layer. Thus, it seems that, based on these
results of gene expression, our strains were not able to modify the
epithelial barrier in a remarkable way. However, it was reported
that probiotics are able to reinforce the intestinal barrier function
by multiple mechanisms (Lebeer et al., 2010a; Rao and Samak,
2013). The efficacy of Bifidobacterium infantis BB-02 to reduce
intestinal injury in NEC was due to its ability to keep claudin-
4 and occludin located in the tight-junction of bifidobacteria-
fed mice (Bergmann et al., 2013). It was also demonstrated
that bioactive factors released by B. infantis (one of the strains
present in the VSL#3 mixture) were also able to reduce gut
permeability by acting upon tight junction proteins (Ewaschuk
et al., 2008). Similarly B. bifidum OLB6378 also favored the
location of tight-junction and adherent-junction proteins, also
being able to induce the synthesis of mucin-3, TFF3, and IL-6
(Khailova et al., 2009). These works, among others, show that
bifidobacteria are able to improve the gut barrier function in
a strain dependent manner. Regarding expression of cytokine
genes in colonic tissue, statistical differences (p < 0.05) were
detected only for pro-inflammatory IL-1β and IFNγ genes and
the anti-inflammatory IL-10 (Table 3); in general, the two first
genes were expressed at a lower rate in the placebo group with
respect to the three bifidobacteria-fed groups, whereas IL-10
gene had significantly lower expression rate only for the ropy
strain Balat_1410S89L. Thus, it seems that this strain induced the
expression of genes that could lead to a mild pro-inflammatory
response, since the ratio TNFα/IL-10 was significantly higher
than that obtained for the other three groups (data not shown).
A similar pro-Th1 profile was obtained with wild-type EPS-
producing B. animalis subsp. lactis strains (one of them also
producing a ropy HMW-EPS) co-cultivated in vitro with PBMC
and GALT (gut associated lymphoid tissue) cells isolated from
naïve rats (Hidalgo-Cantabrana et al., 2014a). Indeed, in the
current study the concentration of these cytokines measured
in blood plasma (Figure 4A) gives TNFα/ IL-10 ratio values of
1.69 ± 0.97 for placebo, 4.32 ± 2.15 for strain 1Balat_1410,
2.77 ± 1.85 for strain Balat_1410, and 10.28 ± 9.15 for
strain Balat_1410S89L. The ratio obtained for the animals fed
with the ropy strain was significantly (p < 0.05) higher than
that obtained for the other three groups of mice. However,
it is worth noting that none of the three strains, or the
placebo, was able to induce a strong immune systemic response
since the values of both cytokines were near (or lower) than
value 1, which is the value of the reference animal group.
Thus, this suggests that our strains, or the skimmed milk
(placebo) used as a protectant for bifidobacteria delivery, did
not contribute to increase the inflammatory process induced
by DSS.
Immune cells isolated from the lymphoid nodes associated
with the gastrointestinal tract were quantified by flow cytrometry
and significant (p< 0.05) variations among the four experimental
groups were detected (Figure 4B). Mice orally receiving the ropy
Balat_1410S89L or the non-ropy Balat_1410 strains presented a
significant reduction in the population of CD4+/CD45+ cells,
which are the markers for helper T-lymphocytes. The number
of this population was even slightly lower than that of the
reference group (value 1). In addition, the group receiving the
strain Balat_1410S89L was the only one significantly different
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TABLE 3 | Relative expression of genes related to immunity of intestinal mucosa in colonic tissue.
Parametera Animal experimentation groups p-value
Placebo Strain 1Balat_1410 Strain Balat_1410 Strain Balat_1410S89L
Cytokines TNFα 8.93±5.42 8.64±3.14 10.48±3.99 7.57±1.89 0.752
IL-10 3.85±1.68b 3.85±1.63b 2.19±0.72a,b 1.75±0.26a 0.041
IL-17 0.93±0.29 0.86±0.29 0.76±0.23 0.83±0.26 0.662
IL-1β 10.98±7.12a 11.88±2.89a 28.94±7.36b 22.98±3.94b 0.001
IL-6 10.61±8.42 11.88±7.14 12.98±6.62 15.27±2.80 0.800
IL-12 0.91±0.41 1.39±1.00 1.52±0.63 0.93±0.28 0.168
TGFβ 2.30±0.98 3.19±2.30 1.96±1.12 1.03±0.75 0.309
IFNγ 0.77±0.69a 2.07±1.72b 2.44±0.94b 2.57±0.95b 0.029
Chemokines iCAM-1 1.91±0.35 1.81±0.93 1.48±0.81 1.52±0.38 0.552
Mcp1 5.12±1.28a 4.93±2.74a 11.41±5.08b 4.39±1.87a 0.001
Tight junctions Occludin 0.66±0.22 0.45±0.22 0.62±0.22 0.46±0.09 0.106
ZO-1 0.69±0.26 0.50±0.24 0.60±0.27 0.48±0.21 0.314
Secretory protein TFF3 1.54±0.56a 2.41±1.15a 3.67±1.29b 1.76±0.37a 0.002
Mucins Muc1 2.92±1.40 3.99±2.00 6.11±3.23 4.52±2.42 0.148
Muc2 0.63±0.38 0.42±0.21 0.49±0.29 0.52±0.12 0.436
Muc3 0.88±0.32 1.24±0.66 1.69±1.00 1.64±1.09 0.158
Enzymes Mmp9 2.52±0.74 3.31±1.60 2.13±0.90 2.78±1.25 0.342
INOS 3.37±2.46 6.52±3.94 10.08±8.63 5.06±1.97 0.096
Values in each DSS-colitic group were referred to the average of those obtained in the control (no-colitic, value = 1) one. P-values from one-way ANOVA tests carried out among four
groups; those values within the same row that do not share a common letter are statistically different according to the mean comparison LSD (p < 0.05).
a IL-, interleukin-; TNFα, tumor necrosis factor α; TGF-β, transforming growth factor β; IFNγ , interferon γ ; MUC-, mucin-; TFF-3, trefoil factor 3; ZO-1, zonula occludens 1; MMP-9,
matrix metallopeptidase 9; iNOS, inducible nitric oxide synthase; ICAM-1, intercellular adhesion molecule.
bThe statistical differences among the four bifidobacterial groups are denoted with different letters (p < 0.05).
Bold values underlines statistical differences according to one-way ANOVA test.
FIGURE 4 | Mean values of relative TNFα and IL-10 cytokines measured in blood samples (A) and relative number of CD4+CD25+ (T helper cells) and
FOXP3 (T regulatory cells) quantified in mesenteric lymphoid nodes (B). Samples were collected after 6-days of DSS-treatment. Values of each DSS-colitic
animal group were referred to as the average of those obtained in the reference group (value = 1). Placebo group ( ), feed B. animalis subsp. lactis 1Balat_1410 ( ),
feed B. animalis subsp. lactis Balat_1410 ( ), feed B. animalis subsp. lactis Balat_1410S89L ( ). Within each parameter: statistical differences among the four groups
are denoted with different letters (p < 0.05).
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from the placebo regarding the number of cells expressing
Foxp3+, which acts as a regulatory factor for differentiation
and function of regulatory T-lymphocytes. Besides, values of
Foxp3+ cells in this group of animals, which also showed a
reduced severity in DAI score, were slightly higher than the value
of the animal reference group. Thus we suggest that the oral
administration of the ropy strain could favor the recruitment
of Treg cells to the intestinal mucosa, which could lead to a
decrease in the severity of the damage caused by DSS. Jeon
et al. (2012) showed in vivo that B. breve Yakult strain was
able to ameliorate T cell-dependent colitis in mice through the
induction of Treg cells toward producing IL-10. Similar results
were obtained with a mixture of five probiotic strains and a mice
model mimicking human Crohn’s disease (Kwon et al., 2010).
These authors also conclude that the efficacy of probiotics was
due to an enrichment of CD4+ Foxp3+ Treg in the inflamed area.
In recent years our group has been working with two models of
isogenic, ropy and non-ropy EPS-producing B. animalis subsp.
lactis strains: wild-types and the recombinant strains used in
the current work. The results regarding the immune response
that both types of strains could elicit are consistent when
immune cells from the same origin are used. That is, all types
of strains are able to induce a mild pro-inflammatory (Th1)
response when a murine (rats or mice) model is used, either
by in vitro (Hidalgo-Cantabrana et al., 2014a) or in vivo (the
current work) approaches. However, the same EPS-producing
strains tested in vitro or ex vivo, with immune cells and colonic
tissue from human origin, had a reduced capability to elicit an
immune response, or displayed an anti-inflammatory cytokine
profile (López et al., 2012; Hidalgo-Cantabrana et al., 2015).
These results underline the strong influence of the biological
model used to test immune capability of strains with probiotic
potential. Variations obtained with both models could be related
to the differences in composition and function of the microbiota
inhabiting the human and mouse intestines (Wos-Oxley et al.,
2012).
Finally, due to the absence of statistical differences among
the three strains we cannot conclude without doubt that the
protective effect of DAI score promoted by strain Balat_1410S89L
was due to the synthesis of the HWM-EPS. However, we
can hypothesize that the ropy HMW-EPS (produced in higher
amounts by this strain) could act as a physical barrier, like
a biofilm, protecting from chemical insults and, consequently,
reducing the severity of the mucosa damage. In this regard,
we have previously shown that the EPS purified from the wild
ropy strain B. animalis subsp. lactis A1dOxR was able to in
vitro counteract the cytotoxic effect of bacterial toxins upon
humans (Caco2 monolayers) or animals (rabbit erythrocyte) cells
(Ruas-Madiedo et al., 2010). Synthesis of EPS by bifidobacteria
in intestinal environmental conditions has not been proved to
date; however, production of EPS by commensal Bacteroides
fragilis in the gut of mice has recently been proved (Geva-
Zatorsky et al., 2015). Thus, this fact would support our
hypothesis that the HMW-EPS from strain B. animalis subsp.
lactis Balat_1410S89L forms an EPS-biofilm protecting, to a
certain degree, the intestinal epithelium from DSS-induced
damage.
CONCLUSION
In this work we have shown that the ropy strain B. animalis
subsp. lactis Balat_1410S89L was able to protect mice from injury
caused by DSS. To date, we have not found modifications in the
expression of genes related to the reinforcement of the intestinal
barrier that could explain the attenuation of chemically-induced
damage; the most relevant immune parameter that could be
related to this fact is the high capability of strain Balat_1410S89L
to induce Treg cells in mesenteric lymphoid nodes which, in
turn, could lead to a localized reduction of the inflammation
at mucosal level. In spite of the only difference among the
three isogenic recombinant strains tested in this study being
the production of a ropy HMW-EPS, we cannot without doubt
attribute the capability to reduce the DSS-induced damage to the
polymer produced by Balat_1410S89L.
There is a lack of consistency in the immune modulation
capability of the ropy HMW-EPS-producing B. animalis subsp.
lactis strains due to the high influence of the biological model
used. However, the ability of the strain Balat_1410S89L to survive
in the mice gut and the absence of adverse effects on the animals,
together with previous in vitro and ex vivo evidence upon human
cells, makes it feasible that the ropy (wild-type) B. animalis subsp.
lactis could be a good candidate to check its anti-inflammatory
ability in patients suffering from intestinal inflammation.
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